EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT - by and between - CUREVAC GMBH - and - BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUGUST 21, 2014Exclusive Collaboration and License Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations
Exhibit 4.5B Description of CureVac's License Agreements with the Ludwig Institute for Cancer Research, the University of Zurich and Geneart AG
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A...Exclusive Collaboration and License Agreement • January 13th, 2021 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Hong Kong
This EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of November 30, 2018 (the “Effective Date”) by and between SHENZHEN SALUBRIS PHARMACEUTICAL CO. LTD., a company organized under the laws of the People’s Republic of China with a place of business at 37F, Tower B, NEO Building, 6009 Shennan Road, Futian District, Shenzhen, China (“Salubris”), and VIRACTA THERAPEUTICS, INC., a Delaware corporation with a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007, USA (“Viracta”). Viracta and Salubris may be referred to herein individually as a “Party” and collectively as the “Parties”.
